70165-31-0

Usage

Uses

6-Cyanonicotinic acid, is used in medicine

Upstream product

• 2398-81-4 Nicotinic acid N-oxide 
• 143-33-9 sodium cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 

Downstream Products

• 313350-44-6 6-cyano-nicotinoyl chloride 
• 953435-32-0 tert-butyl 2-(6-cyanonicotinamido)-4-(thiophen-2-yl)phenylcarbamate 
• 125117-98-8 5-isocyanatopicolinonitrile 
• 58553-48-3 5-(hydroxymethyl)pyridine-2-carbonitrile 
• 709665-27-0 {2-[(6-cyano-pyridine-3-carbonyl)-amino]-phenyl}carbamic acid t-butyl ester 
• 496945-97-2 (2-aminomethyl-5-pyridyl)methanol 
• 89809-65-4 methyl 6-cyanopyridine-3-carboxylate 
• 132225-38-8 methyl p-(6-cyanonicotinamidoacetyl)phenoxyacetate 
• 1095824-56-8 C₁₅H₁₁N₃O₂ 
• 1085938-54-0 C₂₅H₂₁N₇O₃ 
• 1204535-58-9 5-[((2S)-2-Methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]-2-pyridinecarbonitrile 
• 1421502-77-3 C₂₈H₂₂FN₇O₂ 
• 1421502-78-4 C₂₉H₂₄FN₇O₂ 

Relevant academic research and scientific papers

Novel coordinating motifs for lanthanide(III) ions based on 5-(2-pyridyl)tetrazole and 5-(2-pyridyl-1-oxide)tetrazole. Potential new contrast agents

Water-soluble and neutral Ln(III) and Zn (II) complexes of pyridine- and (pyridine-1-oxide)tetrazole have been synthesized and the Gd derivatives have great potential as high-relaxivity low-osmolarity MRI contrast agents.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

Fused bicyclic Gly-Asp β-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere

6-[4-Amidinobenzoyl]amino]-tetralone-2-acetic acid is a potent antagonist of GPIIb-IIIa. Substitution in the meta position of the benzamidine, or replacement with a heteroaryl amidine was tolerated in this series. Use of an acyl-linked 4-alkyl piperidine

Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines

Compounds of the formula I STR1 wherein the groups A, R1, R2 and R3 are as defined in the specification, exhibit valuable pharmacological properties, especially as antifibrotic agents. They are prepared by methods known pe